Design Therapeutics, Inc. (DSGN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027
Design Therapeutics is initiated with a "Hold" rating as its lead candidate, DT-216P2 targets the root cause of Friedreich Ataxia [FA]. The company's 4-week phase 1/2 RESTORE-FA data showed strong biomarker and clinical improvements, but confirmation awaits 12-week results in Q1 2027. Upcoming catalysts include a registrational update in Q4 2026 for DT-216P2 FA and early-stage readouts for DM1 and FECD programs in 2027.
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts
Design Therapeutics has its proprietary GeneTAC platform. This gives them a small-molecule way to target repeat-expansion diseases. Their main value driver and drug candidate is DT-216P2 for FA. DSGN's trial on DT-216P2 is RESTORE-FA. This trial produced data that I believe makes DT-216P2 much more credible.
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know
Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript
Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript
Design Therapeutics, Inc. (DSGN) Presents at Cantor Global Healthcare Conference 2025 Transcript
Design Therapeutics, Inc. (NASDAQ:DSGN ) Cantor Global Healthcare Conference 2025 September 4, 2025 10:55 AM EDT Company Participants Pratik Shah - Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Presentation Joshua Schimmer Biotech Equity Research Analyst All right. We're ready to get started.
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why
Design Therapeutics (DSGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet
The consensus price target hints at a 39.7% upside potential for Design Therapeutics (DSGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
